FoxWayne, Aerami Therapeutics SPAC Deal Worth $195M: Report

FoxWayne

Blank-check company FoxWayne Enterprises Acquisition is in talks to merge with Aerami Therapeutics Holdings, which develops treatments for severe respiratory diseases, in a deal that’s set to value the combined entity at about $195 million, Bloomberg reports, citing people with knowledge of the matter.

The SPAC executed a non-binding letter of intent with Aerami earlier this month, according to a securities filing, which didn’t disclose the transaction size. A deal is yet to be finalized and terms could still change. Read more.

Total
0
Shares
Related Posts
Lucid Motors
Read More

Northern District of California Holds that SPAC Investors have Standing to Sue Regarding Alleged Misstatements About Lucid Motors, But Dismisses Putative Class Action

Plaintiffs who purchased shares in Churchill Capital IV, which later merged with Lucid Motors, alleged that, prior to the merger, the company had made misrepresentations and omissions about its value. However, the court dismissed their claims for failure to identify any misrepresentations because the challenged statements were made before the SPAC and the electric vehicle company had announced that they were in merger discussions.